Ginkgo Bioworks (NYSE:DNA) vs. VectivBio (NASDAQ:VECT) Head to Head Review

Ginkgo Bioworks (NYSE:DNA) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Ginkgo Bioworks and VectivBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	1	3	1	0	2.00
VectivBio	0	2	0	0	2.00

Ginkgo Bioworks presently has a consensus target price of $2.20, suggesting a potential upside of 139.76%. Given Ginkgo Bioworks’ higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than VectivBio.

Institutional and Insider Ownership

78.6% of Ginkgo Bioworks shares are held by institutional investors. 15.1% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Ginkgo Bioworks and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-355.08%	-48.23%	-31.35%
VectivBio	N/A	N/A	N/A

Valuation and Earnings

This table compares Ginkgo Bioworks and VectivBio’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$251.46 million	7.85	-$892.87 million	($0.47)	-1.95
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A

VectivBio has lower revenue, but higher earnings than Ginkgo Bioworks.

Summary

Ginkgo Bioworks beats VectivBio on 5 of the 9 factors compared between the two stocks.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.